@article {Rodriguez:2019:2637-8329:231,
title = "Anti-LGI1 Encephalitis: A Case Report of a Recently Described Disease Entity",
journal = "Neurographics",
parent_itemid = "infobike://asnr/ng",
publishercode ="asnr",
year = "2019",
volume = "9",
number = "3",
publication date ="2019-06-01T00:00:00",
pages = "231-234",
itemtype = "ARTICLE",
issn = "2637-8329",
eissn = "2637-8329",
url = "https://asnr.publisher.ingentaconnect.com/content/asnr/ng/2019/00000009/00000003/art00007",
doi = "doi:10.3174/ng.1800035",
keyword = "LGI1 = leucine-rich glioma-inactivated protein 1, VGKC = voltage-gated potassium channel, FBDS = faciobrachial dystonic seizure, AMPAR = α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor",
author = "Rodriguez, P. and Lancaster, E. and Kurtz, R.M.",
abstract = "Anti-leucine-rich glioma-inactivated protein 1 encephalitis is a rare disease characterized by autoantibodies to a secreted synaptic protein associated with the voltage-gated potassium channel complex and previously attributed to voltage-gated potassium channel antibodies. The classic
clinical presentation is limbic encephalitis with memory loss and pathognomonic faciobrachial dystonic seizures, but patients can also experience paroxysmal dizziness, as well as pain and other symptoms of peripheral nervous system involvement. We present a case of antileucine-rich
glioma-inactivated protein 1 encephalitis as a review of the clinical presentation, laboratory findings, and imaging findings, and discuss prognosis with treatment. A brief review of the antileucine-rich glioma-inactivated protein 1 encephalitis literature is also provided.",
}